Interstitial lung disease associated with drug therapy

Area of Science:

• Pulmonology
• Oncology
• Pharmacology

Background:

• Drug-associated interstitial lung disease (ILD) presents diverse clinical and radiological patterns, complicating diagnosis.
• Acute respiratory failure from drug-induced ILD has rapid onset, making timely diagnosis difficult and often relying on exclusion.
• Cancer chemotherapy, particularly in non-small-cell lung cancer (NSCLC), is frequently linked to acute ILD, often manifesting as diffuse alveolar damage.

Observation:

• This review focuses on NSCLC treatments associated with ILD development.
• The article highlights the need for systematic evaluation of drugs potentially causing ILD.
• A notable difference in ILD reporting rates with gefitinib in advanced NSCLC between Japan and other regions is discussed, though unexplained.

Findings:

• Cancer chemotherapy agents and combined treatments (with or without radiotherapy) increase ILD risk.
• Diagnosis of drug-associated ILD requires integrating clinical, radiological (HRCT), and histological findings.
• Gefitinib use in advanced NSCLC shows unexplained geographical variations in reported ILD incidence.

Implications:

• Understanding drug-induced ILD is crucial for managing NSCLC patients.
• Further research is needed to elucidate the mechanisms and epidemiology of drug-associated ILD.
• Clarifying geographical differences in ILD reporting may reveal important risk factors or genetic predispositions.